Radiolabeled 2'-fluorodeoxyuracil-beta-D-arabinofuranoside (FAU) and 2'-fluoro-5-methyldeoxyuracil-beta -D-arabinofuranoside (FMAU) as tumor-imaging agents in mice
The purpose of the present study was to evaluate, in conjunction with the National Cancer Institute, the feasibility of using two thymidine analogs, 2'-fluorodeoxyuracil-beta-D-arabinofuranoside (FAU, NSC-678515) and 2'-fluoro-5-methyldeoxyuracil-beta-D-arabinofuranoside (FMAU, NSC-678516)...
Gespeichert in:
Veröffentlicht in: | Cancer chemotherapy and pharmacology 2002-05, Vol.49 (5), p.419-424 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The purpose of the present study was to evaluate, in conjunction with the National Cancer Institute, the feasibility of using two thymidine analogs, 2'-fluorodeoxyuracil-beta-D-arabinofuranoside (FAU, NSC-678515) and 2'-fluoro-5-methyldeoxyuracil-beta-D-arabinofuranoside (FMAU, NSC-678516), as 18-fluorine-labeled positron emission tomography (PET) imaging agents.
The in vivo distribution and DNA incorporation of [2-(14)C]FAU, [2-(14)C]FMAU, and [2-(14)C]thymidine (as a control) were studied in SCID mice bearing human xenografts of T-cell leukemia CCRF-CEM. Levels of drug-associated radioactivity in blood, tumor and normal tissues including liver, kidneys, heart, lungs, spleen, brain, and skeletal muscle were determined.
At 1 h after dosing, radioactivity from all three compounds was distributed in a generally nonspecific manner, except that spleen and tumor tissue had relatively high concentrations of radioactivity from [(14)C]thymidine. At 4 h after dosing, the concentrations of radioactivity from [(14)C]thymidine and [(14)C]FMAU were relatively high in spleen and tumor tissue, and that from [(14)C]FAU was highest in tumor tissue. The tumor/skeletal muscle concentration ratios were 2.25+/-0.69 and 3.07+/-0.42 for [(14)C]FAU and [(14)C]FMAU, respectively. At 24 h after dosing, only spleen and tumor tissues contained appreciable amounts of radioactivity from either compound. In tumor tissue, the levels of radioactivity from [(14)C]FMAU were two- to threefold greater than those from [(14)C]thymidine or [(14)C]FAU. Examination of purified genomic DNA from tumor, liver, kidneys, brain, and skeletal muscle showed that, at 24 h after dosing, only DNA from tumor tissue contained appreciable concentrations of radioactivity. Radioactivity from [(14)C]FMAU in tumor DNA was 45% greater than that from [(14)C]thymidine and about threefold greater than that from [(14)C]FAU.
The extent of accumulation of [(14)C]FMAU in tumor tissue and incorporation into tumor DNA indicate that [(18)F]FMAU could be useful as a functional PET tumor-imaging agent. |
---|---|
ISSN: | 0344-5704 1432-0843 |
DOI: | 10.1007/s00280-002-0433-7 |